FAM225A

Across TCGA pan-cancer cohorts, FAM225A RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of FAM225A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FAM225A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FAM225A is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

KIRC, HNSC, and STAD are the cancer types where FAM225A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM225A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	+0.272	<.001	11	view →
HNSC	All	IV	+0.178	<.001	9	view →
STAD	All	All	+0.155	.009	8	view →
KIRP	Male	All	+0.140	<.001	8	view →
COAD	All	II,III,IV	+0.102	.002	6	view →
ESCA	All	II,III,IV	+0.235	.012	3	view →
READ	Male	All	+0.270	.044	2	view →
PRAD	All	All	−0.063	.024	2	view →
BLCA	Female	IV	+0.110	.024	1	view →
LIHC	Female	II,III,IV	+0.055	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

FAM225A–KIRC

Open the KIRC breakdown →